we've been over all these sleight of hand attacks against officers of the co many times- which leads me to wonder why all these continual attacks on the same issues -why all the personal attacks against co officials if such are not the outworkings of a vendetta against those people-such attacks usually come from simple vendettas(past stock losses) to personal vendettas (as in disgruntled former employees or management).
I cant speak to the N Assay patent since we dont have recent patent updates on that? but other patents are basically routinely mentioned as company property -and NNLX has stated, as posted many times, that NNLX has exclusive rights to the flatpack technology for example.
To the extent I find mention of patents by NNLX they are usually if not always[cant find references to such immediately re N-Assay partly due to lack of recent posted updates re such on website-NNLX has said website will be updated if not a new website -and I never saw any statement re timing of such-long ago ichallenged naysayers to provide proof of such and never heard a word] couched in terms of the company, not persons.
The legal system leaves much to be desired but one rule they enforce is fiduciary duty- highest duties known to the law - dealing w others property. Officers and board members,advisory or not, owe these duties to the company. That includes NNLX past advisory board member-their patent attorney,who on behalf of the company owed those responsibilities to the company,and filed most if not all of those patents during her reign on the advisory board
I have posted the law re defamation -due to continual personal attacks by naysayers against NNLX officials and longs.
So now i guess such defamation is being posted in terms of hypotheticals.
I dont know the exact relationship between researchers associated w NNLX like the Faros, but at least one Faro is on the advisory board -and thus in that relationship owes fiduciary duties to NNLX- all officers and board members,advisory or not - do.
I have not seen nor has any proof been presented that any officer or board member has violated any duty to NNLX.
Thus these personal attacks by the same people -some likely posing under dual aliases or new aliases after being banned by this site - now couched in terms of hypotheticals- are likely due to vendettas-and as articles in my sticky point out such vendettas are often carried out by disgruntled ex employees or ex mgmt trying to impose duties or fault beyond that required by the law.
the only guarantees in life are death and taxes and that you will lose money on average at a casino etc.
so if you dont trust officers etc get out and put your money in bonds guaranteed by the full faith and credit of the USA- which is not foolproof either due to possible govt bankruptcy or emp etc attack by our enemies.
so you might as well pose hypotheticals re a major near earth object destroying advanced life on this planet as such objects regularly pass close by without any present guaranteed solution and some are not detected till they pass by.
doesnt the world have enough trouble without falsely impugning officers and directors without proof?-many who do so are of course shorters who know that among rebellious humans fear is more powerful than faith.
A quick perusal from the website:[emphasis added]
New Technologies
The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.
In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013.
Financial Matters
As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000. That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO[over 100k at one time], and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors --- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.
In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.
Dec 24, 2013:
NanoLogix is pleased to announce the addition of new member to the Science Advisory Board:
Dr. Sebastian Faro rejoins the SAB after an absence of over a year when he resigned due to a policy change at UTHSC-Houston that required all personnel affiliated with UTHSC to shed any corporate associations. Dr. Faro is now affiliated with The Woman's Hospital of Houston, which does not restrict physicians. associations. The company welcomes Dr. Faro back to the Science Advisory Board.
Sounds like patents where possible are listed in NNLX name as follows:
April 02, 2013:
NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world.
NNLX as far I can see presents patents as owned by the company [dont know about new N assay but the same rules of fiduciary duty apply]
August 25, 2010: New Patent Granted
The company has been issued U.S. patent #7,781,159 for its invention of a method and device for the rapid detection, enumeration and identification of microorganisms. This is one of two foundational patents granted this year for our BioNano technologies.
from 2009: The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
I cant speak to the N Assay patent since we dont have recent patent updates on that? but other patents are basically routinely mentioned as company property -and NNLX has stated, as posted many times, that NNLX has exclusive rights to the flatpack technology for example.
To the extent I find mention of patents by NNLX they are usually if not always[cant find references to such immediately re N-Assay partly due to lack of recent posted updates re such on website-NNLX has said website will be updated if not a new website -and I never saw any statement re timing of such-long ago ichallenged naysayers to provide proof of such and never heard a word] couched in terms of the company, not persons.
The legal system leaves much to be desired but one rule they enforce is fiduciary duty- highest duties known to the law - dealing w others property. Officers and board members,advisory or not, owe these duties to the company. That includes NNLX past advisory board member-their patent attorney,who on behalf of the company owed those responsibilities to the company,and filed most if not all of those patents during her reign on the advisory board
I have posted the law re defamation -due to continual personal attacks by naysayers against NNLX officials and longs.
So now i guess such defamation is being posted in terms of hypotheticals.
I dont know the exact relationship between researchers associated w NNLX like the Faros, but at least one Faro is on the advisory board -and thus in that relationship owes fiduciary duties to NNLX- all officers and board members,advisory or not - do.
I have not seen nor has any proof been presented that any officer or board member has violated any duty to NNLX.
Thus these personal attacks by the same people -some likely posing under dual aliases or new aliases after being banned by this site - now couched in terms of hypotheticals- are likely due to vendettas-and as articles in my sticky point out such vendettas are often carried out by disgruntled ex employees or ex mgmt trying to impose duties or fault beyond that required by the law.
the only guarantees in life are death and taxes and that you will lose money on average at a casino etc.
so if you dont trust officers etc get out and put your money in bonds guaranteed by the full faith and credit of the USA- which is not foolproof either due to possible govt bankruptcy or emp etc attack by our enemies.
so you might as well pose hypotheticals re a major near earth object destroying advanced life on this planet as such objects regularly pass close by without any present guaranteed solution and some are not detected till they pass by.
doesnt the world have enough trouble without falsely impugning officers and directors without proof?-many who do so are of course shorters who know that among rebellious humans fear is more powerful than faith.
A quick perusal from the website:[emphasis added]
New Technologies
The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.
In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013.
Financial Matters
As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000. That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO[over 100k at one time], and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors --- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.
In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.
Dec 24, 2013:
NanoLogix is pleased to announce the addition of new member to the Science Advisory Board:
Dr. Sebastian Faro rejoins the SAB after an absence of over a year when he resigned due to a policy change at UTHSC-Houston that required all personnel affiliated with UTHSC to shed any corporate associations. Dr. Faro is now affiliated with The Woman's Hospital of Houston, which does not restrict physicians. associations. The company welcomes Dr. Faro back to the Science Advisory Board.
Sounds like patents where possible are listed in NNLX name as follows:
April 02, 2013:
NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world.
NNLX as far I can see presents patents as owned by the company [dont know about new N assay but the same rules of fiduciary duty apply]
August 25, 2010: New Patent Granted
The company has been issued U.S. patent #7,781,159 for its invention of a method and device for the rapid detection, enumeration and identification of microorganisms. This is one of two foundational patents granted this year for our BioNano technologies.
from 2009: The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
6
